These findings, which show an increase over time in the use of triple drug PEP for infants Y-27632 cost born to HIV-infected women, highlight the impact that changes in national guidelines have had on clinical practice. Combined with effective antiretroviral therapy in pregnancy and careful management of delivery, neonatal prophylaxis contributes to the success

of MTCT prevention programmes across the UK and Ireland. National surveillance of obstetric and paediatric HIV infection is undertaken through the National Study of HIV in Pregnancy and Childhood (NSHPC) in collaboration with the Health Protection Agency Centre for Infections, and Health Protection Scotland. We gratefully acknowledge the contribution of the midwives, obstetricians, genito-urinary physicians, paediatricians, clinical nurse specialists and all other colleagues who report to the NSHPC through the British Paediatric Surveillance Selleckchem Roxadustat Unit of the Royal College of Paediatrics and Child Health, and the obstetric reporting scheme run under the auspices of the Royal College of Obstetricians and Gynaecologists. We thank Janet Masters who co-ordinates the study and manages the data, and provided comments on drafts

of this paper, and Icina Shakes for administrative support. We also thank Mario Cortina-Borja, Catherine Peckham and Hermione Lyall for their helpful comments on this manuscript. Author contributions: HH-S and CLT carried out the statistical analyses and jointly drafted the paper. All authors contributed to the interpretation of the results, commented on all drafts of the paper, and approved the final version.

PAT is the guarantor. Sources of financial support: The National Study of HIV in Pregnancy and Childhood receives core funding from the Health Protection Agency (grant number GHP/003/013/003). CLT was funded by the UK Medical Research DOK2 Council (MRC) between 2006 and 2009 (grant number G0501895). This work was undertaken at the Centre for Paediatric Epidemiology and Biostatistics which benefits from funding support from the MRC in its capacity as the MRC Centre of Epidemiology for Child Health. The University College London (UCL) Institute of Child Health receives a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme. Any views expressed in this paper are those of the authors, and not necessarily those of the funders. Ethics approval: Ethics approval for the NSHPC was renewed following review by the London Multi-Centre Research Ethics Committee in 2004 (ref. MREC/04/2/009). Disclosure of interests: We declare that we have no conflicts of interest. “
“Treated HIV-1-infected patients with lipodystrophy often develop insulin resistance and proatherogenic dyslipidaemia.